ID: ALA4459995

Max Phase: Preclinical

Molecular Formula: C17H12FN3

Molecular Weight: 277.30

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C#CCNc1ccc2ncc(-c3ccc(F)cc3)nc2c1

Standard InChI:  InChI=1S/C17H12FN3/c1-2-9-19-14-7-8-15-16(10-14)21-17(11-20-15)12-3-5-13(18)6-4-12/h1,3-8,10-11,19H,9H2

Standard InChI Key:  AYLBGFJZWMQQAX-UHFFFAOYSA-N

Associated Targets(non-human)

Astrocyte 64 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 277.30Molecular Weight (Monoisotopic): 277.1015AlogP: 3.48#Rotatable Bonds: 3
Polar Surface Area: 37.81Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 3.06CX LogP: 3.18CX LogD: 3.18
Aromatic Rings: 3Heavy Atoms: 21QED Weighted: 0.74Np Likeness Score: -1.87

References

1. Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B..  (2016)  New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.,  59  (13): [PMID:27341519] [10.1021/acs.jmedchem.6b00297]

Source